Press Releases

CohBar, Inc.’s CEO Simon Allen to Present at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York

Menlo Park, California – March 30 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will present an overview of the Company and its clinical development program at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York City. read-more

CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

Menlo Park, California – February 21 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it has completed a study to evaluate the potential efficacy of its lead drug candidates, MOTS-c peptide analogs CB4209 and CB4211, in a well-established preclinical model of nonalcoholic steatohepatitis (NASH). With these positive study results, the Company continues to advance its lead drug candidates through IND enabling activities, with plans to initiate human clinical trials in early 2018. read-more

CohBar, Inc.’s CEO Simon Allen to Present at the 2017 BIO CEO & Investor Conference in New York

Menlo Park, California – February 9, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will present an overview of the Company and its clinical development program at the 2017 BIO CEO & Investor Conference in New York City. read-more

CohBar, Inc.’s CEO Simon Allen to Present at the 9th Annual Biotech Showcase in San Francisco

Menlo Park, California – January 10, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the Company will present at the 9th Annual Biotech Showcase Conference in San Francisco on Wednesday, January 11th, 2017 at 2:30pm Pacific Time. CohBar’s Chief Executive Officer, Simon Allen, will discuss the Company’s recent announcements about its clinical development program and its ongoing discovery of new biologically active peptides in the mitochondrial genome. read-more

CohBar, Inc. Continues Exploration of Mitochondrial Genome and Expansion of Its IP Portfolio With Filing of 29 New Provisional Patents

Menlo Park, California – December 6, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the discovery of a number of new biologically active peptides encoded within the mitochondrial genome and the filing of 29 additional related provisional patent applications. The provisional patent applications also cover novel analogs developed by CohBar that are based on the biologically active peptides. During 2016, the Company filed over 50 provisional patents related to its mitochondrial peptide discoveries and novel analogs. read-more

CohBar, Inc.’s CEO Simon Allen to Present at BIO Investor Forum 2016

Menlo Park, California – October 18, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat diseases associated with aging, today announced that its Chief Executive Officer Simon Allen will present an overview of the company and its recent developments at the 2016 BIO Investor Forum in San Francisco. Mr. Allen will discuss CohBar’s recent announcements regarding the advancement of its preclinical candidates CB4209 and CB4211 into IND-enabling activities and the company’s discovery of new biologically active peptides in the mitochondrial genome. read-more

CohBar, Inc. Announces Discovery of New Peptides in the Mitochondrial Genome Company Expands IP Portfolio with 25 New Provisional Patent Applications

Menlo Park, California – October 13, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat diseases associated with aging, today announced the discovery of a large number of new biologically active peptides encoded within the genome of the mitochondria, together with the filing of 25 new provisional patent applications. The company is evaluating these peptides as possible additions to its pipeline of MBTs, and expects to file additional patent applications going forward. read-more

CohBar Advances First-in-Class Mitochondria Based Therapeutic to IND-Enabling Activities

Menlo Park, California – September 30, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) for age-related diseases, today announced the selection of two analogs from the company’s MOTS-c program for advancement into IND-enabling activities. The drug candidates, CB4209 and CB4211, have demonstrated significant therapeutic potential in pre-clinical models for the treatment of obesity, with additional confirmatory studies planned to determine therapeutic potential for the treatment of nonalcoholic steatohepatitis (NASH), and as a potential add-on to other drugs for the treatment of type 2 diabetes. read-more

CohBar, Inc. Announces Preclinical Proof-of-principle Publication for SHLP Mitochondrial-derived Peptides and their Role in Metabolic Regulation and Cell Viability
SHLP Family of Peptide Hormones, Shows Therapeutic Potential for Treating Diseases of Aging

Menlo Park, California - April 11, 2016 - CohBar, Inc. (OTCQX: CWBR and TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today announced that researchers at the University of Southern California (USC), in collaboration with investigators at the Institute for Aging Research at the Albert Einstein College of Medicine of Yeshiva University (Einstein), have demonstrated the ability of small humanin-like peptides (SHLPs), a novel family of six peptide hormones discovered by the group, to regulate metabolism and cell viability in preclinical studies. The research, “Naturally Occurring Mitochondrial-derived Peptides are Age-dependent Regulators of Apoptosis, Insulin Sensitivity, and Inflammatory Markers,” appears online and in the April 2016 issue of Aging. CohBar has the exclusive license for the development of SHLPs into therapeutics. read-more

CohBar, Inc. Appoints Simon Allen as Chief Executive Officer

Menlo Park, California – March 8, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today reported that Simon Allen has been appointed as the company’s Chief Executive Officer. Mr. Allen brings to CohBar more than 20 years of industry experience and success both as a scientist and a business executive.  Former CohBar CEO Jon Stern has assumed a new role going forward as the company’s Chief Operating Officer. read-more

CohBar, Inc. Engages Torrey Hills Capital
CohBar issues warrants to complete agreement

Menlo Park, California – February 3, 2016 - CohBar, Inc. (OTCQX: CWBR and TSX-V: COB.U) (“CohBar”), an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, announces further to its news release dated January 7, 2016 that it has granted a warrant to purchase up to 125,000 shares of the CohBar’s common stock exercisable at a price of $1.15 per share for a period of three years to San Diego Torrey Hills Capital, Inc. ("Torrey Hills Capital"), a Rancho Santa Fe, California based investor relations firm, pursuant to a previously announced investor relations agreement. read-more

CohBar, Inc. Engages Torrey Hills Capital
Firm to target investors focused on microcap markets

Menlo Park, California – January 7, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today announced that it has engaged San Diego Torrey Hills Capital, Inc. ("Torrey Hills Capital"), a Rancho Santa Fe, California-based investor relations firm specializing in small and micro-cap companies, to provide market awareness and investor relations services to the Company, subject to TSX Venture Exchange acceptance read-more

CohBar Announces Commencement of Trading on the OTCQX Marketplace

Menlo Park, California  – May 20, 2015 – CohBar, Inc. (OTCQX: CWBR and TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics for diseases associated with aging, announced that its shares will begin trading today on the OTCQX® Best marketplace in the U.S. under the symbol “CWBR.” read-more

CohBar, Inc. Announces Publication of Preclinical Proof-of-Principle of MOTS-c and its Role in Metabolic Regulation

Pasadena, California  – March 3, 2015 – CohBar, Inc. (TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics to treat diseases associated with aging, today announced that researchers have discovered MOTS-c, a new mitochondrial-derived peptide hormone that prevents obesity caused by a high-fat diet and stimulates the metabolism in the same way as exercise. read-more